ds-2325a
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 20, 2022 (NCT05388903)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Kallikrein 1ANTAGONIST
KLK1 antagonist
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095274 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05979831 | Phase 1/Phase 2 (Phase 2) | Sep 28, 2023 | Daiichi Sankyo |
| NCT05583669 | Phase 1 | Nov 8, 2022 | Daiichi Sankyo |
| NCT05388903 | Phase 1 | Jun 20, 2022 | Daiichi Sankyo |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1